# Ziprasidone in the Psychosis Prodrome

> **NCT00635700** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 51 (actual)

## Conditions studied

- Psychosis Prodrome

## Interventions

- **DRUG:** ziprasidone
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00635700
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635700, "Ziprasidone in the Psychosis Prodrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00635700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*